New COVID-19 clinical trials at UW–Madison and UW Health will study antibody approach
The trials center around an “antibody cocktail” called REGN-COV2, which was created by the New York-based pharmaceutical company Regeneron.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
